Danish children hospitalized by super strength Inno Pharma vitamin D

By Gareth Macdonald

- Last updated on GMT

Danish children hospitalized by super strength Inno Pharma vitamin D
Several children have been hospitalized by a vitamin D supplement made by Inno Pharma according to regulators in Denmark.

The Danish Health Authority (Sundhedsstyrelsen) advised people not to use "Inno Pharma vitamin D3-dråber" – sold by health food organization Helsam or pharmacy chain Matas – in a warning letter published on July 29​.

An authority spokeswoman told us “Due to a calculation error the company Inno Pharma has produced a vitamin D food supplement with a 75 times higher dose than intended​” adding that “production has been stopped and the sold products has been recalled​”

She also confirmed that “several young children have been hospitalized as a result of ingesting this particular food supplement​.”  

According to the organization 87 of the 150 children known to have used the super strength product had elevated vitamin D levels.

High vitamin D levels may result in a condition called hypercalcemia – high blood calcium – which is known to interfere with normal cardiac functioning. It is also linked to the formation of kidney stones.

According to Sundhedsstyrelsen, 74 of the children tested had high levels in their blood.

Inno Pharma is not associated with Pfizer’s InnoPharma subsidiary.

Related news

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Follow us

Products

View more

Webinars